A detailed history of Black Rock Inc. transactions in Bluebird Bio, Inc. stock. As of the latest transaction made, Black Rock Inc. holds 15,442,212 shares of BLUE stock, worth $131 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
15,442,212
Previous 15,178,562 1.74%
Holding current value
$131 Million
Previous $19.4 Million 22.11%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

BUY
$0.85 - $1.26 $224,102 - $332,199
263,650 Added 1.74%
15,442,212 $15.1 Million
Q1 2024

May 10, 2024

BUY
$0.91 - $1.75 $5.64 Million - $10.8 Million
6,195,561 Added 68.97%
15,178,562 $19.4 Million
Q4 2023

Feb 13, 2024

BUY
$1.32 - $4.83 $204,056 - $746,660
154,588 Added 1.75%
8,983,001 $12.4 Million
Q3 2023

Nov 13, 2023

BUY
$3.02 - $4.05 $107,786 - $144,548
35,691 Added 0.41%
8,828,413 $26.8 Million
Q2 2023

Aug 11, 2023

SELL
$2.79 - $5.03 $427,581 - $770,872
-153,255 Reduced 1.71%
8,792,722 $28.9 Million
Q1 2023

May 12, 2023

BUY
$3.14 - $8.22 $4.95 Million - $13 Million
1,577,315 Added 21.41%
8,945,977 $28.4 Million
Q4 2022

Feb 13, 2023

BUY
$5.77 - $8.49 $2.71 Million - $3.99 Million
469,687 Added 6.81%
7,368,662 $51 Million
Q3 2022

Nov 14, 2022

BUY
$3.75 - $7.39 $4.07 Million - $8.02 Million
1,085,635 Added 18.67%
6,898,975 $43.7 Million
Q2 2022

Aug 12, 2022

SELL
$2.94 - $5.23 $69,886 - $124,322
-23,771 Reduced 0.41%
5,813,340 $24.1 Million
Q1 2022

May 12, 2022

SELL
$4.07 - $10.6 $304,806 - $793,844
-74,891 Reduced 1.27%
5,837,111 $28.3 Million
Q4 2021

Feb 10, 2022

BUY
$8.96 - $16.31 $1.27 Million - $2.32 Million
142,293 Added 2.47%
5,912,002 $59.1 Million
Q3 2021

Nov 09, 2021

SELL
$11.24 - $21.0 $1.57 Million - $2.93 Million
-139,388 Reduced 2.36%
5,769,709 $110 Million
Q2 2021

Aug 11, 2021

BUY
$18.04 - $22.09 $107 Million - $131 Million
5,909,097 New
5,909,097 $189 Million

Others Institutions Holding BLUE

About bluebird bio, Inc.


  • Ticker BLUE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 77,121,800
  • Market Cap $656M
  • Description
  • bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include betibeglogene autotemcel for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell ...
More about BLUE
Track This Portfolio

Track Black Rock Inc. Portfolio

Follow Black Rock Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

News

Stay updated on Black Rock Inc. with notifications on news.